| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Addition of bevacizumab enhances antitumor activity of erlotinib against non-small cell lung cancer xenografts depending on VEGF expression
|
Li, Heyan
|
|
2014
|
74 |
6 |
p. 1297-1305
|
artikel
|
| 2 |
A Phase II trial of axitinib in patients with various histologic subtypes of advanced thyroid cancer: long-term outcomes and pharmacokinetic/pharmacodynamic analyses
|
Cohen, E. E. W.
|
|
2014
|
74 |
6 |
p. 1261-1270
|
artikel
|
| 3 |
A retrospective study of docetaxel or paclitaxel in patients with advanced or recurrent esophageal squamous cell carcinoma who previously received fluoropyrimidine- and platinum-based chemotherapy
|
Shirakawa, Tsuyoshi
|
|
2014
|
74 |
6 |
p. 1207-1215
|
artikel
|
| 4 |
Clinical usefulness of therapeutic concentration monitoring for imatinib dosage individualization: results from a randomized controlled trial
|
Gotta, V.
|
|
2014
|
74 |
6 |
p. 1307-1319
|
artikel
|
| 5 |
Docetaxel, cisplatin, and fluorouracil combination in neoadjuvant setting in the treatment of locally advanced gastric adenocarcinoma: Phase II NEOTAX study
|
Ozdemir, Nuriye
|
|
2014
|
74 |
6 |
p. 1139-1147
|
artikel
|
| 6 |
Effect of front-line chemotherapy on circulating CK-19 mRNA-positive cells in patients with metastatic breast cancer
|
Georgoulias, V.
|
|
2014
|
74 |
6 |
p. 1217-1225
|
artikel
|
| 7 |
Effects of combined treatment of α-tocopherol, l-ascorbic acid, selenium and zinc on bleomycin, etoposide and cisplatin-induced alterations in testosterone synthesis pathway in rats
|
Kilarkaje, Narayana
|
|
2014
|
74 |
6 |
p. 1175-1189
|
artikel
|
| 8 |
Folate levels measured by LC–MS/MS in patients with colorectal cancer treated with different leucovorin dosages
|
Taflin, Helena
|
|
2014
|
74 |
6 |
p. 1167-1174
|
artikel
|
| 9 |
MicroRNAs: a new key in lung cancer
|
Zhang, Yunlong
|
|
2014
|
74 |
6 |
p. 1105-1111
|
artikel
|
| 10 |
Nonclinical pharmacokinetics and activity of etirinotecan pegol (NKTR-102), a long-acting topoisomerase 1 inhibitor, in multiple cancer models
|
Hoch, Ute
|
|
2014
|
74 |
6 |
p. 1125-1137
|
artikel
|
| 11 |
Pharmacokinetics of endoxifen and tamoxifen in female mice: implications for comparative in vivo activity studies
|
Reid, Joel M.
|
|
2014
|
74 |
6 |
p. 1271-1278
|
artikel
|
| 12 |
Pharmacokinetics of single-agent axitinib across multiple solid tumor types
|
Tortorici, Michael A.
|
|
2014
|
74 |
6 |
p. 1279-1289
|
artikel
|
| 13 |
Phase I clinical trial of temsirolimus and vinorelbine in advanced solid tumors
|
Piatek, Caroline I.
|
|
2014
|
74 |
6 |
p. 1227-1234
|
artikel
|
| 14 |
Phase I dose escalation and pharmacokinetic study of oral gefitinib and irinotecan in children with refractory solid tumors
|
Brennan, R. C.
|
|
2014
|
74 |
6 |
p. 1191-1198
|
artikel
|
| 15 |
Phase II study of adjuvant vinorelbine and cisplatin in Japanese patients with completely resected stage II and III non-small cell lung cancer
|
Sonobe, Makoto
|
|
2014
|
74 |
6 |
p. 1199-1206
|
artikel
|
| 16 |
Phase II trial of carboplatin and pemetrexed as first-line chemotherapy for non-squamous non-small cell lung cancer, and correlation between the efficacy/toxicity and genetic polymorphisms associated with pemetrexed metabolism: Hokkaido Lung Cancer Clinical Study Group Trial (HOT) 0902
|
Kanazawa, Kenya
|
|
2014
|
74 |
6 |
p. 1149-1157
|
artikel
|
| 17 |
Phase I study of cabazitaxel plus cisplatin in patients with advanced solid tumors: study to evaluate the impact of cytochrome P450 3A inhibitors (aprepitant, ketoconazole) or inducers (rifampin) on the pharmacokinetics of cabazitaxel
|
Sarantopoulos, John
|
|
2014
|
74 |
6 |
p. 1113-1124
|
artikel
|
| 18 |
Phase I study of intravenously administered ATI-1123, a liposomal docetaxel formulation in patients with advanced solid tumors
|
Mahalingam, Devalingam
|
|
|
74 |
6 |
p. 1241-1250
|
artikel
|
| 19 |
Phase I study of intravenously administered ATI-1123, a liposomal docetaxel formulation in patients with advanced solid tumors
|
Mahalingam, Devalingam
|
|
2014
|
74 |
6 |
p. 1241-1250
|
artikel
|
| 20 |
Risk factors for 6-month continuation of S-1 adjuvant chemotherapy for resected pancreatic cancer
|
Aoyama, Toru
|
|
2014
|
74 |
6 |
p. 1235-1240
|
artikel
|
| 21 |
Safety and pharmacokinetics of S-1 in a recurrent colon cancer patient with chronic myeloid leukemia treated with dasatinib: a case report
|
Sueda, Toshinori
|
|
2014
|
74 |
6 |
p. 1321-1324
|
artikel
|
| 22 |
The safety and efficacy of paclitaxel and carboplatin with or without bevacizumab for treating patients with advanced nonsquamous non-small cell lung cancer with interstitial lung disease
|
Shimizu, Ryoko
|
|
2014
|
74 |
6 |
p. 1159-1166
|
artikel
|
| 23 |
Trastuzumab, in combination with carboplatin and docetaxel, does not prolong the QT interval of patients with HER2-positive metastatic or locally advanced inoperable solid tumors: results from a phase Ib study
|
Xu, Na
|
|
2014
|
74 |
6 |
p. 1251-1260
|
artikel
|
| 24 |
Treatment outcomes of gemcitabine alone versus gemcitabine plus platinum for advanced biliary tract cancer: a Korean Cancer Study Group retrospective analysis
|
Hwang, In Gyu
|
|
2014
|
74 |
6 |
p. 1291-1296
|
artikel
|
Tijdschrift beschrijving